AML patients with activated RAS mutation also exhibit high inflammatory responses, and an article by Hamarsheh et al. showed that AML patients with KRAS mutations, a subtype of the RAS gene, have activated inflammasome pathways, with NLRP3/caspase1/IL-1β being the major contributing axis [59].Therefore, these results reveal the heterogeneity of inflammatory responses in different clinicopathological features, and the combined assessment of them can be helpful for the diagnosis and treatment of AML. This evidence concerns the gene KRAS and acute myeloid leukemia.